Optimi Health Corp. Secures Regulatory Approval for Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression
Reuters
Sep 03
<a href="https://laohu8.com/S/OPTHF">Optimi Health</a> Corp. Secures Regulatory Approval for Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression
Optimi Health Corp., a Canadian manufacturer of GMP psychedelic medicines, has announced the commercial launch of its natural psilocybin capsules in Australia. This approval allows the capsules, which are prescribed for Treatment-Resistant Depression (TRD), to be distributed under Australia's Authorised Prescriber Scheme. The initial shipment included 1,000 capsules, each containing 5mg of naturally-derived psilocybin, manufactured at Optimi's GMP-licensed facility in British Columbia. The launch follows successful MDMA sales for PTSD treatment in Australia, marking a significant step for Optimi in delivering scalable psychedelic treatments. Optimi's authorized commercial partner, Mind Medicine Australia, will oversee distribution and patient coordination through the country's network of clinics and hospitals.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 264871) on September 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.